Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 1;125(17):3040-3049.
doi: 10.1002/cncr.32174. Epub 2019 May 23.

The effect of treatment on patient-reported distress after breast cancer diagnosis

Affiliations

The effect of treatment on patient-reported distress after breast cancer diagnosis

Oluwadamilola M Fayanju et al. Cancer. .

Abstract

Background: The National Comprehensive Cancer Network (NCCN) Distress Thermometer (DT) uses a 10-point scale (in which 0 indicates no distress and 10 indicates extreme distress) to measure patient-reported distress. In the current study, the authors sought to examine the relationship between treatment and NCCN DT scores in patients with breast cancer over time.

Methods: The authors included women aged ≥18 years who were diagnosed with stage 0 to stage IV breast cancer (according to the seventh edition of the American Joint Commission on Cancer staging system) at a 3-hospital health system from January 2014 to July 2016. Linear mixed effects models adjusted for covariates including stage of disease, race/ethnicity, insurance, and treatment sequence (neoadjuvant vs adjuvant) were used to estimate adjusted mean changes in the DT score (MSCs) per week for patients undergoing lumpectomy, mastectomy only, and mastectomy with reconstruction (MR).

Results: The authors analyzed 12,569 encounters for 1029 unique patients (median score, 4; median follow-up, 67 weeks). Patients treated with MR (118 patients) were younger and more likely to be married, white, and privately insured compared with patients undergoing lumpectomy (620 patients) and mastectomy only (291 patients) (all P < .01). After adjusting for covariates, distress scores were found to decline significantly across all 3 surgical cohorts, with patients undergoing MR found to have both the most preoperative distress and the greatest decline in distress prior to surgery (MSC/week: -0.073 for MR vs -0.031 for lumpectomy vs -0.033 for mastectomy only; P = .001). Neoadjuvant therapy was associated with a longitudinal decline in distress for patients treated with lumpectomy (-1.023) and mastectomy only (-0.964). Over time, ductal carcinoma in situ (-0.503) and black race (-1.198) were found to be associated with declining distress among patients treated with lumpectomy and MR, respectively, whereas divorced patients who were treated with mastectomy only (0.948) and single patients treated with lumpectomy (0.476) experienced increased distress (all P < .05).

Conclusions: When examined longitudinally in consecutive patients, the NCCN DT can provide patient-reported data to inform expectations and guide targeted support for patients with breast cancer.

Keywords: breast cancer; distress; health disparities; modifiable risk factors; patient-reported outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest to Disclose: None

Figures

Figure 1.
Figure 1.
Patient Flow Diagram - Newly Diagnosed Breast Cancer Patients at Duke, January 2014-July 2016 DT, distress thermometer. *Confirmed on manual reveiw
Figure 2.
Figure 2.
Adjusted Mean Change in NCCN Distress Thermometer Score per Week, Breast Cancer Patients at Duke, January 2014-July 2016 (n=1029): (a) Linear Trend Plot (b) Scatter Plot with Loess Smoothing and Scaled Density Curve – Treatment Sequence
Figure 2.
Figure 2.
Adjusted Mean Change in NCCN Distress Thermometer Score per Week, Breast Cancer Patients at Duke, January 2014-July 2016 (n=1029): (a) Linear Trend Plot (b) Scatter Plot with Loess Smoothing and Scaled Density Curve – Treatment Sequence

References

    1. Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34(6):557–565. - PMC - PubMed
    1. Yee MK, Sereika SM, Bender CM, Brufsky AM, Connolly MC, Rosenzweig MQ. Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer. Cancer. 2017;123(11):2061–2069. - PubMed
    1. Simpson JS, Carlson LE, Trew ME. Effect of group therapy for breast cancer on healthcare utilization. Cancer practice. 2001;9(1):19–26. - PubMed
    1. Basch E, Deal AM, Dueck AC, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. Jama. 2017;318(2):197–198. - PMC - PubMed
    1. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008;26(8):1355–1363. - PubMed

Publication types